Atherogenic lipid indices and metabolic syndrome in polycystic ovary syndrome: a comparative cross-sectional study.
- 1Department of Clinical Biochemistry, Institute of Medicine, Maharajgunj Medical Campus, Tribhuvan University, Kathmandu, Nepal.
- 2Department of Clinical Biochemistry, Institute of Medicine, Maharajgunj Medical Campus, Tribhuvan University, Kathmandu, Nepal. [email protected].
- 3Department of Obstetrics & Gynaecology, Institute of Medicine, Maharajgunj Medical Campus, Tribhuvan University, Kathmandu, Nepal.
Abstract
Background
Polycystic Ovary Syndrome (PCOS) is one of the causes of infertility in females. It is also associated with hyperandrogenism and hyperinsulinemia. With these hormonal imbalances, there can be an equally important risk of cardiometabolic consequences as a result of altered atherogenic lipid indices and metabolic syndrome which has not been much explored in context of Nepal. The purpose of this study was to delve into different lipid profile parameters to calculate atherogenic lipid indices to identify the metabolic syndrome (MetS) and cardiovascular risk in PCOS.Methods
We enrolled 70 PCOS and 60 age-matched non-PCOS females visiting the Infertility Clinic at the Department of Obstetrics and Gynecology at Tribhuvan University Teaching Hospital. After written informed consent, anthropometric measurements as well as a blood samples were taken and biochemical analysis of glucose, total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides were measured in Abbott ARCHITECT ci4100 autoanalyzer. Based on the examined variables, various formulas to assess atherogenic risk and metabolic syndrome [Castelli's risk index I & II (CRI-I, CRI-II), atherogenic coefficient (AC), atherogenic index of plasma (AIP), lipoprotein combined index (LCI), lipid accumulation product (LAP)] were applied. Descriptive and inferential analysis was carried in SPSS version 23.0. A p-value ≤ 0.05 was considered as significant.Results
The PCOS group had higher atherogenic lipid indices (CRI-I, CRI-II, AIP, AC, LCI and LAP) compared to their non-PCOS counterparts. The prevalence of metabolic syndrome (MetS) was also higher in the PCOS (81.4%, n = 57) compared to non-PCOS (30%, n = 18). The LAP score was found to be an efficient indicator of MetS in the PCOS patients with an AUC of 0.829 (p < 0.001), with the sensitivity and specificity of 80% and 94.5% respectively.Conclusions
Our study showed a higher frequency of MetS and cardiovascular risk in PCOS as determined by higher atherogenic lipid indices than non PCOS. LAP score was the most efficient indicator of MetS.
Related
- Triglyceride-Glucose Index and Systemic Inflammatory Markers in Polyendocrine Metabolic Ovarian Syndrome (Polycystic Ovary Syndrome): A Cross-Sectional Study
- Knowledge gaps regarding polycystic ovary syndrome/polyendocrine metabolic ovarian syndrome among medical students: a cross-sectional study
- Comparative Effects of Myo-Inositol, Metformin, Berberine, and Combination Therapy on Metabolic, Anthropometric and Hormonal Parameters in Women with Polycystic Ovary Syndrome: A 6-Month Observational Cohort Study
- The role of sitagliptin in modifying metabolic, hormonal and clinical parameters in polycystic ovarian syndrome patients: a randomized controlled trial
- Polyendocrine metabolic ovarian syndrome (PMOS)/polycystic ovary syndrome (PCOS): current and future trends
BibTeX
@article{baidya2026atherogenic,
title = {{Atherogenic lipid indices and metabolic syndrome in polycystic ovary syndrome: a comparative cross-sectional study.}},
author = {Sujata Baidya and Pratibha Kandel and Smrity Rajkarnikar and Sagar Parajuli and Apeksha Niraula and Eans Tara Tuladhar and Raju Kumar Dubey and Mithileshwer Raut and Aseem Bhattarai and Poonam Koirala and Vijay Kumar Sharma},
journal = {BMC women's health},
year = {2026},
month = jul,
doi = {10.1186/s12905-026-04734-2},
url = {https://europepmc.org/article/MED/42902247},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Atherogenic lipid indices and metabolic syndrome in polycystic ovary syndrome: a comparative cross-sectional study.
AU - Sujata Baidya
AU - Pratibha Kandel
AU - Smrity Rajkarnikar
AU - Sagar Parajuli
AU - Apeksha Niraula
AU - Eans Tara Tuladhar
AU - Raju Kumar Dubey
AU - Mithileshwer Raut
AU - Aseem Bhattarai
AU - Poonam Koirala
AU - Vijay Kumar Sharma
PY - 2026
DA - 2026/07/01
JO - BMC women's health
DO - 10.1186/s12905-026-04734-2
UR - https://europepmc.org/article/MED/42902247
AB - Background Polycystic Ovary Syndrome (PCOS) is one of the causes of infertility in females. It is also associated with hyperandrogenism and hyperinsulinemia. With these hormonal imbalances, there can be an equally important risk of cardiometabolic consequences as a result of altered atherogenic lipid indices and metabolic syndrome which has not been much explored in context of Nepal. The purpose of this study was to delve into different lipid profile parameters to calculate atherogenic lipid indices to identify the metabolic syndrome (MetS) and cardiovascular risk in PCOS.Methods We enrolled 70 PCOS and 60 age-matched non-PCOS females visiting the Infertility Clinic at the Department of Obstetrics and Gynecology at Tribhuvan University Teaching Hospital. After written informed consent, anthropometric measurements as well as a blood samples were taken and biochemical analysis of glucose, total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides were measured in Abbott ARCHITECT ci4100 autoanalyzer. Based on the examined variables, various formulas to assess atherogenic risk and metabolic syndrome [Castelli's risk index I & II (CRI-I, CRI-II), atherogenic coefficient (AC), atherogenic index of plasma (AIP), lipoprotein combined index (LCI), lipid accumulation product (LAP)] were applied. Descriptive and inferential analysis was carried in SPSS version 23.0. A p-value ≤ 0.05 was considered as significant.Results The PCOS group had higher atherogenic lipid indices (CRI-I, CRI-II, AIP, AC, LCI and LAP) compared to their non-PCOS counterparts. The prevalence of metabolic syndrome (MetS) was also higher in the PCOS (81.4%, n = 57) compared to non-PCOS (30%, n = 18). The LAP score was found to be an efficient indicator of MetS in the PCOS patients with an AUC of 0.829 (p < 0.001), with the sensitivity and specificity of 80% and 94.5% respectively.Conclusions Our study showed a higher frequency of MetS and cardiovascular risk in PCOS as determined by higher atherogenic lipid indices than non PCOS. LAP score was the most efficient indicator of MetS.
SN - 1472-6874
ER -